Table 3 Efficacy and safety data from the two trials comparing apixaban with the European enoxaparin dose as thromboprophylaxis following elective total hip or knee replacement surgery [25, 26]
| Â | 2.5 mg apixaban initiated post-surgery | 40 mg enoxaparin initiated 12 h pre-surgery |
|---|---|---|
ADVANCE-2 trial (knee replacement) | ||
Total VTE and all-cause mortality (primary efficacy end-point) | 147/976 (15.1%) | 243/997 (24.4%) |
Major bleeding | 9/1501 (0.6%) | 14/1508 (0.9%) |
ADVANCE-3 trial (hip replacement) | ||
Total VTE and all-cause mortality (primary efficacy end-point) | 27/1949 (1.4%) | 74/1917 (3.9%) |
Major bleeding | 22/2673 (0.8%) | 18/2659 (0.7%) |